Recent findings have suggested the role of genetic mutations in AD epidemiology, such as mutations in the processing of Amyloid beta (Aβ) peptide and Tau protein, dysfunctions of synaptic and mitochondrial proteins, neurovascular alterations, oxidative stress, and neuroinflammation, hence the disruption of brain plasticity [3]. Here, MAPT is linked to Alzheimer disease.